Population Pharmacokinetics of Oral Gecacitinib in Healthy Subjects and Patients with Autoimmune and Inflammatory Diseases.
Gecacitinib is a novel, broad‐spectrum Janus kinase (JAK) inhibitor being developed for the treatment of myelofibrosis, severe alopecia areata, ankylosing spondylitis, and atopic dermatitis. This study aimed to develop population pharmacokinetic (PopPK) models for gecacitinib and its metabolites ZG0...
| Publicado en: | Journal of Clinical Pharmacology Vol. 66; no. 6; pp. 1 - 17 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | equations & formulas research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Jun2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |